Xilio Therapeutics (Nasdaq: XLO) has reported initial results from its Phase II trial of vilastobart, an anti-CTLA-4 therapy, in combination with Roche's (ROG: SIX) Tecentriq (atezolizumab).
The trial is testing the combo as an option for certain people with colorectal cancer. Presented at a meeting of the American Society of Clinical Oncology, the mixed results appeared to worry investors on Wednesday, sending shares down by around a third.
The trial involved 40 patients, 70% of whom had undergone at least three prior lines of anti-cancer therapy. One positive sign was an objective response rate (ORR) of 27% from a subset of patients, including three partial responses.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze